The activity of pyrazoline B compound in inhibiting proliferation of breast cancer cells with human epidermal growth factor receptor 2 overexpression
Pyrazoline B inhibited cell cycle progression, induced apoptosis and necrosis, downregulated PI3K/mTOR signalling, and elevated ROS levels in MCF 7/HER-2 cells compared with the untreated control cells. These findings suggest that pyrazoline B is a promising candidate for development as a novel anticancer agent.
Authors
- Ema Damayanti (ORCID: https://orcid.org/0000-0002-4017-0499)
- Syukur Berkat Waruwu (ORCID: https://orcid.org/0000-0002-7912-4705)
- Mustofa Mustofa
- Denny Satria (ORCID: https://orcid.org/0000-0003-4724-3256)
- Pamungkas Bagus Satriyo (ORCID: https://orcid.org/0000-0001-9544-3119)
- Eti Nurwening Sholikhah (ORCID: https://orcid.org/0000-0002-6545-8691)
- Tutik Dwi Wahyuningsih (ORCID: https://orcid.org/0000-0001-5741-2848)
- Muhammad Hasan Bashari (ORCID: https://orcid.org/0000-0001-7298-0317)
- Hesti Lina Wiraswati (ORCID: https://orcid.org/0000-0003-2462-6633)
Institutions
- Universitas Gadjah Mada (ID)
- Universitas Sumatera Utara (ID)
- National Research and Innovation Agency (ID)
- Padjadjaran University (ID)
Publication Details
- Journal
- Współczesna Onkologia
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5114/wo.2025.155694
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00